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his is an open access article under the CC B
ttp://dx.doi.org/10.1016/j.jmoldx.2017.07.003Genetic testing of BRCA1/2 includes screening for single nucleotide variants and small insertions/de-
letions and for larger copy number variations (CNVs), primarily by Sanger sequencing and multiplex
ligation-dependent probe ampliﬁcation (MLPA). With the advent of next-generation sequencing (NGS),
it has become feasible to provide CNV information and sequence data using a single platform. We report
the use of NGS gene panel sequencing on the Illumina MiSeq platform and JSI SeqPilot SeqNext software
to call germline CNVs in BRCA1 and BRCA2. For validation 18 different BRCA1/BRCA2 CNVs previously
identiﬁed by MLPA in 48 Danish breast and/or ovarian cancer families were analyzed. Moreover, 120
patient samples previously determined as negative for BRCA1/BRCA2 CNVs by MLPA were included in the
analysis. Comparison of the NGS data with the data from MLPA revealed that the sensitivity was 100%,
whereas the speciﬁcity was 95%. Taken together, this study validates a one-step bioinformatics work-
ﬂow to call germline BRCA1/2 CNVs using data obtained by NGS of a breast cancer gene panel. The work-
ﬂow represents a robust and easy-to-use method for full BRCA1/2 screening, which can be easily
implemented in routine diagnostic testing and adapted to genes other than BRCA1/2. (J Mol Diagn
2017, 19: 809e816; http://dx.doi.org/10.1016/j.jmoldx.2017.07.003)Supported by the Center for Genomic Medicine, Rigshospitalet,
Copenhagen, Denmark.
Disclosures: None declared.Loss-of-function mutations in tumor suppressor genes BRCA1
(MIM#113705) and BRCA2 (MIM#600185) predispose to
breast and ovarian cancer.1e3 Genetic testing includes detec-
tion of single nucleotide changes, small insertions/deletions,
and copy number variations (CNVs) deﬁned as gain or loss of
DNA fragments >1 kb. Recently, a total number of 81 and 17
CNVs have been reported for BRCA1 and BRCA2, respec-
tively.4 The prevalence of BRCA1/2 CNVs varies greatly
among different populations, and numerous BRCA1 founder
events have been identiﬁed, for instance in the Dutch5,6 and
Danish7 populations. The highest contribution of BRCA1
CNVs is observed in the Dutch population in which 27% to
36% of all germline BRCA1 mutations are CNVs.5,6,8 In
Denmark, CNVs account for 12.5% of all disease-causing
BRCA1 mutations identiﬁed in high-risk breast and ovarian
cancer families,7 a number resembling that of the French,9stigative Pathology and the Association for M
Y-NC-ND license (http://creativecommons.orgSpanish,10 and German11 populations. The proportion of
CNVs in the BRCA2 gene is generally much smaller, ranging
from 0% to 8%.7,12e17 The large difference in the number of
genomic rearrangements between the two BRCA genes has
been explained by the higher number of Alu repeats in
BRCA1, which are known to increase the occurrence of
rearrangements.18
For more than a decade, the golden standard for mutational
screening of BRCA1/2 has been Sanger sequencing and multi-
plex ligation-dependent probe ampliﬁcation (MLPA) for small
nucleotide variations and larger genetic rearrangements,
respectively, but these techniques are being superseded byolecular Pathology. Published by Elsevier Inc.
/licenses/by-nc-nd/4.0).
Schmidt et alnext-generation sequencing (NGS). Massive parallel
sequencing of genomic regions using NGS allows molecular
diagnostic laboratories to increase sample throughput, reduce
the turn-around time, and analyze more disease-related genes
simultaneously. As a result, many diagnostic laboratories have
tested and implemented NGS-based platforms as their main
technology for clinical testing.19e25 The main challenge of
implementing NGS in diagnostics is the development of a
simple and robust bioinformatics pipeline, fulﬁlling the
requirement of quality control for diagnosis.26 Here, we validate
anNGS-basedmethod to identifyBRCA1/2CNVs.TargetDNA
sequences were captured by hybridization, and the gene panels
were sequenced on the Illumina MiSeq platform. Mapping of
sequencing reads followed by variant calling, including CNV,
was performed using the SeqPilot SeqNext software version 4.0
(JSIMedical Systems, Ettenheim,Germany). The validation set-
up included a total number of 18 different BRCA1/2 CNVs
previously identiﬁed by MLPA and 120 patient samples deter-
mined as negative for BRCA1/BRCA2 CNVs by MLPA.
Materials and Methods
CNV Nomenclature
The BRCA1/2 CNVs are named according to the Human
Genome Variation Society (http://www.HGVS.org/varnomen,
last accessed January 3, 2017) guidelines for CNVs with
characterized and uncharacterized breakpoints. For CNVs
with uncharacterized breakpoints the nomenclature indicates
that the breakpoints are located somewhere in the intronic
sequences ﬂanking the deleted or duplicated exons.
DNA Puriﬁcation
Genomic DNA was puriﬁed from whole blood samples using
the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) or the
ReliaPrep Large Volume HT gDNA Isolation Kit (Promega,
Madison, WI) using a Tecan Freedom EVO HSM2.0 Work-
station according to the manufacturer’s instructions.
MLPA Analysis
MLPA analysis was performed according to the manufacturer’s
instructions (MRC-Holland, Amsterdam, the Netherlands)
using the SALSAP002 andP087BRCA1 andSALSAP045 and
P077 BRCA2MLPA Kits as recently described.7
Gene Panel Sequencing
A gene panel comprising six breast and ovarian cancer-
predisposing genes (BRCA1, BRCA2, RAD51C, CDH1,
PTEN, and TP53) was examined by NGS. Target DNA se-
quences were captured using biotinylated oligos provided
through Roche NimbleGen (Roche, Basel, Switzerland). The
oligos were designed to capture all exons, including 100 bp of
ﬂanking intronic sequence, from the six genes transcribed to the810following transcripts: NM_007294 (BRCA1), NM_000059
(BRCA2), NM_058216 (RAD51C), NM_004360 (CDH1),
NM_000314 (PTEN), and NM_000546 (TP53), respectively.
Library was constructed using 500 ng of genomic DNA. The
DNA was fragmented into an average size of 200 bp using a
Covaris S2 AFA ultrasonicator, and adaptors from Illumina
(Illumina, SanDiego, CA) or Roche NimbleGenwere ligated to
the fragments. Illumina adaptors included in the TruSeq DNA
LT Sample Preparation Kit were attached using an SPRI-works
System I for Illumina Genome Analyzer (Beckman Coulter,
Brea, CA). Adaptor sequences provided by Roche NimbleGen
(SeqCap Adaptor Kit A/B) were ligated using the KAPA HTP
Library Preparation Kit Illumina on a Sciclone G3 NGS
Workstation (Perkin Elmer, Waltham, MA). Sequence capture
was performedusing the double capture protocol as describedby
Roche NimbleGen, where 6 to 12 samples are multiplexed
before hybridization. Importantly, these 6 to 12 samples must
follow the same type of library construction to successfully call
CNVs. Finally, 2  76-bp paired-end sequencing was per-
formed on the IlluminaMiSeq platform to an average depth of 5
to 600 with a minimum coverage of at least 50.CNV Detection
CNVs were identiﬁed from the Illumina sequencing data by
loading FASTQ ﬁles into the SeqPilot SeqNext software.
This software detects CNVs based on the coverage in spe-
ciﬁc target regions of interest (ROIs). The ROIs are deﬁned
as exons  50-bp intronic sequence in BRCA1/2 (and
RAD51C, CDH1, PTEN, and TP53) and 24 control frag-
ments localized on several different chromosomes. A min-
imum of six samples in a batch were simultaneously
analyzed to obtain at least ﬁve control samples for each
sample, assuming they did not contain common CNVs.
Therefore, including family members in a batch should be
avoided. To normalize the absolute amounts of BRCA1/
BRCA2 ROIs, the average coverage for the 24 control
fragments is calculated for each sample. Then the relative
coverage was calculated for each BRCA1/BRCA2 ROI
against the average coverage of the control fragments. These
calculations are applied to all control samples and the
analyzed sample. The percentage of the relative coverages
of every speciﬁc BRCA1/BRCA2 ROI in the analyzed
sample is then compared with the average relative coverage
of the control samples for the same ROI. If the ratio between
the patient and control samples exceeds the lower (70%) or
upper (135%) limit, it is regarded as a deletion or duplica-
tion, and the ﬁnding is veriﬁed by MLPA analysis. In cases
when NGS and MLPA results are conﬂicting, new blood
sample is requested and the MLPA analysis is repeated.Results
By MLPA analysis, a total of 48 families positive for a
BRCA1/2 CNV were previously identiﬁed. Forty-ﬁvejmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 1 Large CNVs in BRCA1 and BRCA2 Identiﬁed in Danish Breast and/or Ovarian Cancer Families by MLPA and NGS Analysis
Families, n Gene MLPA Genomic alteration CNV calling from NGS data* Reference
1 BRCA1 Del exon 1e3 c.(?_-232)_(134þ1_135-1)del E1 52%; E2 52%; E3 48% 27,28
1 BRCA1 Del exon 1e7 c.(?_-232)_(441þ1_442-1)del E1 66%; E2 48%; E3 56%; E5
48%; E6 52%; E7 54%
29e31
1 BRCA1 Del exon 1e14 c.(?_-232)_(4484þ1_4485-1)del E1 49%; E2 47%; E3 50%; E5 58%;
E6 51%; E7 49%; E8 57%;
E9 50%; E10 52%; E11 54%;
E12 58%; E13 56%; E14 55%
32
2 BRCA1 Del exon 3 c.(80þ1_81-1)_(134þ1_135-1)del E3 62% 16,28,33
24 BRCA1 Del exon 3e16 c.81-1018_4986þ716del46586 E3 52%; E5 54%; E6 58%; E7 56%;
E8 51%; E9 53%; E10 53%;
E11 60%; E12 52%; E13 54%;
E14 51%; E15 54%; E16 52%
7,34
2 BRCA1 Del exon 5e7 c.136-623_441þ1958del4994 E5 56%; E6 52%; E7 52% 7,35e37
2 BRCA1 Dup exon 13 c.(4185þ1_4186-1)_(4357þ1_4358-1)
dup
E13 172% 5,7,28,38e47
4 BRCA1 Del exon 13e15 c.(4185þ1_4186-1)_(4675þ1_4676-1)
del
E13 50%; E14 51%; E15 48% 30,34,43,48,49
1 BRCA1 Del exon 17 c.(4986þ1_4987-1)_(5074þ1_5075-1)
del
E17 54% 11,28,30,35,37,50e52
1 BRCA1 Del exon 17e18 c.4986þ498_5152þ171del6727 E17 50%; E18 54% 7
2 BRCA1 Del exon 17e19 c.(4986þ1_4987-1)_(5193þ1_5194-1)
del
E17 52%; E18 54%; E19 58% 7,46,53
1 BRCA1 Del exon 18e19 c.(5074þ1_5075-1)_(5193þ1_5194-1)
del
E18 49%; E19 47% 30,54e56
1 BRCA1 Del exon 19 c.(5152þ1_5153-1)_(5193þ1_5194-1)
del
E19 50% 7
1 BRCA1 Del Exon 22 c.(5332þ1_5333-1)_(5406þ1_5407-1)
del
E22 63% 6,28,30,39,40,57,58
1 BRCA1 Del exon 23e24 c.(5406þ1_5407-1)_(1383_?)del E23 51%; E24 56% 4,10,30,35,59
1 BRCA2 Del exon 12e16 c.(6841þ1_6842-1)_(7805þ1_7806-1)
del
E12 54%; E13 48%; E14 46%;
E15 51%; E16 51%
60
1 BRCA2 Dup exon 17e20 c.(7805þ1_7806-1)_(8632þ1_8633-1)
dup
E17 190%; E18 165%;
E19 183%; E20 176%
61
1 BRCA2 Del exon 20 c.8531_8632þ1054del E20 51% 7,15,56
*Coverage 70%: deletion; coverage 130%: duplication.
CNV, copy number variation; Del, deletion; Dup, duplication; MLPA, multiplex ligation-dependent probe ampliﬁcation; NGS, next-generation sequencing.
Detection of BRCA1/BRCA2 CNVs Using NGSfamilies carried a BRCA1 mutation, whereas only three
families had a BRCA2 mutation. Eighteen unique
CNVs were identiﬁedd15 in BRCA1 and three in
BRCA2dincluding 16 gross deletions and two large du-
plications (Table 1).
To validate the hybridization-based gene panel set-up for
CNV analysis, all of the BRCA1/2 CNVs described above
were examined. Coding regions plus 100 bp of ﬂanking
intronic sequence of six genes were captured by hybridi-
zation and sequenced on the Illumina MiSeq platform. The
samples were hybridized in batches with at least six bar-
coded diagnostic samples to obtain a minimum of ﬁve
control samples, assuming they do not contain common
CNVs. Sequence data were processed and analyzed using
the SeqPilot SeqNext software, and CNVs were called based
on differences in read depth. After normalization, a relative
coverage was calculated for each BRCA1/BRCA2 ROI in the
patient sample of interest and control samples. All 18 CNVsThe Journal of Molecular Diagnostics - jmd.amjpathol.orgtested were identiﬁed in the NGS data. The CNVs consisted
of the following aberrations: BRCA1 exon 1 to
3 deletion, BRCA1 exon 1 to 7 deletion, BRCA1 exon 1 to
14 deletion, BRCA1 exon 3 deletion, BRCA1 exon 3 to 16
deletion, BRCA1 exon 5 to 7 deletion, BRCA1 exon 13
duplication, BRCA1 exon 13 to 15 deletion, BRCA1 exon 17
deletion, BRCA1 exon 17 to 18 deletion, BRCA1 exon 17 to
19 deletion, BRCA1 exon 18 to 19 deletion, BRCA1 exon 19
deletion, BRCA1 exon 22 deletion, BRCA1 exon 23 to 24
deletion, BRCA2 exon 12 to 16 deletion, BRCA2 exon 17 to
20 duplication, and BRCA2 exon 20 deletion (Table 1,
Figure 1, and Supplemental Figures S1eS5). The average
relative coverage compared with controls was 52.9% (range,
47% to 66%) for an exon deletion and 177.2% (range, 165%
to 190%) for an exon duplication. Thus, there was a 100%
concordance between the CNVs identiﬁed by MLPA and
the CNVs identiﬁed by NGS analysis. To examine the
speciﬁcity of the analysis 120 samples previously reported811
Figure 1 Visualization of BRCA2 germline exon 17 to 20 duplication in JSI SeqPilot SeqNext software. The upper histogram shows the relative coverage of
every target region of interest (ROI) of the patient sample in green and the average relative target coverage of control samples in blue. The lower histogram
shows the ratio of the relative coverage of target ROIs calculated from patient versus controls. If the ratio exceeds the deﬁned limits indicated by red lines, the
bars change from light blue to dark blue, indicating a genomic change. A lower limit (lower red dotted line) of 70% (deletion) and an upper limit (upper red
dotted line) of 135% (duplication) was used. Data are expressed as means  SD of control samples.
Table 2 Average Relative Coverage of Two Independent
Sequencing Runs of BRCA1 CNVs
CNVs
RUN 1
Average relative
coverage,
% (range)
RUN 2
Average relative
coverage,
% (range)
BRCA1 exon 1e3 deletion 52 (49e58) 47 (43e49)
BRCA1 exon 1e7 deletion
(sample 1)
53 (51e56) 49 (47e51)
BRCA1 exon 1e7 deletion
(sample 2)
52 (48e60) 50 (47e56)
BRCA1 exon 1e7 deletion
(sample 3)
49 (45e59) 48 (42e68)
BRCA1 exon 1e14 deletion 51 (47e56) 50 (45e54)
BRCA1 exon 3e16 deletion 50 (47e53) 51 (48e56)
BRCA1 exon 5e7 deletion 47 (43e50) 46 (43e49)
BRCA1 exon 13e15 deletion 50 (48e52) 49 (49e50)
BRCA1 exon 17 deletion 52 52
BRCA1 exon 19 deletion 56 54
CNV, copy number variation.
Schmidt et alas CNV negative by MLPA analysis were analyzed. Four
samples had between one and four exon deletions and/or
duplications in the BRCA1 and/or BRCA2 genes with an
average relative coverage of 60.3% (range, 52% to 70%) for
exon deletions and 138.8% (range, 137% to 143%) for exon
duplications. In three of these four samples the deletions/
duplications were separated by exons with normal average
relative coverage. Moreover, two samples revealed multiple
(>20) deletions and duplications. Overall, the results
showed a 95% concordance between the MLPA and NGS
results.
The interbatch reproducibility of the method was tested
by repeating the library construction and targeted
sequencing of 10 samples without BRCA1/BRCA2 CNVs
and 10 samples with BRCA1 CNVs, including exon 1 to 3
deletion, exon 1 to 7 deletion (three different samples), exon
1 to 14 deletion, exon 3 to 16 deletion, exon 5 to 7 deletion,
exon 13 to 15 deletion, exon 17 deletion, and exon 19
deletion. For all samples the result resembled the previous
result. No deletions or duplication were called by repeated
analysis of the 10 samples without BRCA1/BRCA2 CNVs
(Table 2).
In addition, 23 family members found to be BRCA1 CNV
positive by MLPA analysis were examined for BRCA1 CNVs
by NGS analysis, including seven cases with exon 3 deletion,
seven cases with exon 3 to 16 deletion, three cases with exon
17 to 19 deletion, two cases of exon 1 to 7 deletion, one case
of exon 1 to 14 deletion, one case of exon 5 to 7 deletion, one
case of exon 13 to 15 deletion, and one case of exon 19
deletion. In all cases the deletion was identiﬁed by NGS
analysis with an average relative coverage of 50.7% (range,
43% to 60%). Moreover, the intrabatch reproducibility of the
method was tested by repeating the library construction and
targeted sequencing of two samples (BRCA1 deletion of exon
17 and BRCA1 deletion of exons 3 to 16) six times each in one
batch containing 12 samples, respectively. The data revealed812an average relative coverage of 48.2% (range, 43% to 53%) for
the exon 17 deletion and 51.5% (range, 42% to 68%) for exon
3 to 16 deletion.
Finally, the inﬂuence of the number of identical dupli-
cations in a single batch on the CNV calling were examined.
Data containing one, two, or three identical duplications
(BRCA1 exon 13 duplication) in a batch of six samples
(Supplemental Figure S6) were analyzed. The data revealed
that including one sample in a batch resulted in a BRCA1
exon 13 CNV call of 147%, including two samples resulted
in a BRCA1 exon 13 CNV call of 135%, whereas including
three samples resulted in a BRCA1 exon 13 CNV call of
127%, which does not exceed the limit of 135%. Inclusion
of three identical exon 13 duplications however did notjmd.amjpathol.org - The Journal of Molecular Diagnostics
Detection of BRCA1/BRCA2 CNVs Using NGSinﬂuence the CNV call of samples without rearrangement
(data not shown). The analysis was also performed with
identical deletions (BRCA1 exon 3 to 16 deletion) in a single
batch of six samples. In this case it was possible to include
up to three samples with deletion and still call the CNV
(Supplemental Figure S7). However, this in contrast
inﬂuenced the CNV call of samples without rearrangement
and led to the identiﬁcation of a false-positive duplication
call (Supplemental Figure S8).Discussion
In recent years, NGS has paved its way into the molecular
diagnostic set-up and made it possible to screen more genes
and patients simultaneously. According to data from the
European Molecular Genetics Quality Network, the number
of laboratories using NGS for BRCA1/2 screening has
increased. In 2012/2013 only 6% of the laboratories
involved in external quality assessment of BRCA1 and
BRCA2 mutations used NGS, but by 2014 and 2015 this
number had increased to 19% and 32%, respectively. These
ﬁgures reﬂect the general trend toward using NGS-based
approaches for genetic screening and consequently the
need for validation of simple and accurate bioinformatics
pipelines.
In this study, we validated a simple Illumina NGS set-up
based on the capture of a panel of six genes involved in
hereditary breast and ovarian cancer to identify BRCA1/2
CNVs in routine genetic testing. In total, 18 large rear-
rangements in BRCA1/2 were examined, and the analysis
showed a 100% concordance between NGS and MLPA
results. Moreover, the results were reproducible. The NGS
set-up usually included hybridization of 12 barcoded
samples in the same reaction. However, it is possible to
include a minimum of two samples per batch if they are
prepared in the same library construction and do not
contain the same CNV in BRCA1 or BRCA2. We recom-
mend a minimum of ﬁve controls for each sample in a
single batch. This makes it possible to analyze data even if
some of the samples have false-positive CNVs or if pa-
tients with identical CNVs are included in the batch.
Identical CNVs can disturb the CNV calling, a problem
that also affects MLPA analysis. Therefore, it is also rec-
ommended that family members are not analyzed in the
same batch. Our data however suggest that two samples
with identical duplications (BRCA1 exon 13 duplication) or
identical deletions (BRCA1 exon 3 to 16 deletion) of six
samples do not affect the CNV calling of a true duplication
or deletion or the CNV-negative samples in the batch. In
contrast, including three identical deletions results in a
false-positive duplication call in samples without rear-
rangements, whereas inclusion of three identical duplica-
tions results in a false-negative call of a sample with a
BRCA1 exon 13 duplication. Given the rarity of BRCA1
and BRCA2 CNVs in the Danish population, the risk ofThe Journal of Molecular Diagnostics - jmd.amjpathol.orgincluding more than two samples with identical CNV,
when excluding family members, is considered very low.
The speciﬁcity of the NGS analysis was found to be 95%.
Six of 120 CNV-negative samples revealed a false-positive
CNV result by NGS analysis. In these cases the average
relative coverage was 60.3% for exon deletions and 138.8%
for exon duplications, which is closer to the threshold values of
70% and 135% than true deletions/duplications. However, the
data indicate that all deletions/duplications called by NGS
analysis should be veriﬁed by MLPA analysis. In cases when
NGS and MLPA data are conﬂicting, a second blood sample is
requested from the patient and the MLPA analysis is repeated.
Previous publications have described other streamlined
NGS pipelines for diagnostic screening of BRCA1 and
BRCA2.23,25 In these studies, 13 and 6 large BRCA1/2
CNVs were included, respectively.23,25 In contrast to these
studies that involved more complicated bioinformatics
work-ﬂows, our set-up relies on a single software for
detection of both CNVs, single nucleotide variants, and
small deletions/insertions. The SeqPilot SeqNext software is
very simple and user-friendly, and the processing time for
full BRCA1/2 mutational screening only takes a few minutes
after upload of data.
The NGS-based sequencing and CNV calling has several
advantages compared with the standard diagnostic set-up
involving Sanger sequencing and MLPA. The most obvious
is that only one method is required to perform full screening
of BRCA1 and BRCA2, thus reducing the diagnostic turn-
around and costs per sample. Second, NGS requires a lower
amount of DNA for multiple analyses. Third, calling CNVs
using an NGS-based strategy avoids one group of false-
positive results that are a feature of MLPA because of
mutations present in the MLPA primer hybridization site.
All of these advantages are important in a diagnostic setting;
however, the NGS-based method also has limitations,
especially for pseudogenes because of the hybridization-
based capture approach. We have observed false-positive
CNVs in PTEN because of the existence of highly homol-
ogous pseudogenes.62 MLPA is also affected by some of
these problems, but to a lesser extent, because probes are
designed to avoid the pseudogenes. To circumvent the in-
ﬂuence of pseudogenes, future set-ups could include an
amplicon-based NGS method designed to preclude exon
ampliﬁcation from pseudogenes.Conclusion
This study describes the validation of a simple one-step
bioinformatics pipeline for CNV calling in BRCA1 and
BRCA2 using Illumina gene panel data and the SeqPilot
SeqNext software. Because of the existence of many
different CNVs in BRCA1 and BRCA2, these genes consti-
tute a good model for testing the diagnostic NGS set-up.25
We infer that the set-up may be adapted to other genes
involved in hereditary diseases.813
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